The UNICORN study is a model example that explored RW survival and resistance in the context of EGFR mutations, showing that compound EGFRm NSCLC (containing both uncommon and common EGFR mutations) had better outcomes with the third-generation TKI osmertinib.28 This evidence concerns the gene EGFR and non-small cell lung carcinoma.